Induction immunochemotherapy followed by definitive radiotherapy in patients with limited-stage small cell lung cancer: a multicenter study
The standard treatment for limited-stage small cell lung cancer (LS-SCLC) is systemic chemotherapy with concurrent or sequential radiotherapy[1][1]. The recent ADRIATIC trial demonstrated that durvalumab, as a consolidation therapy, could significantly improve the overall survival \[OS\] ( P = 0.01
Authors
- Q-X Wang
- Y Q Chen
- Liu Y (ORCID: https://orcid.org/0009-0004-3901-1652)
- Junxu Wen
- Heng Zhao
- Xinrui Yu
- Zhaoqin Huang (ORCID: https://orcid.org/0000-0002-2069-3401)
- Xiangjiao Meng (ORCID: https://orcid.org/0000-0001-7380-5510)
- Xiaoyan Yin
- Shanshan Li
Institutions
- Shandong Tumor Hospital (CN)
- Shandong Provincial Hospital (CN)
- Central Hospital of Zibo (CN)
- Affiliated Hospital of Jining Medical University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Cancer Biology and Medicine
- Published
- 2026-05-11
- DOI
- https://doi.org/10.20892/j.issn.2095-3941.2025.0800
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00